Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports

Released April 1, 2022

Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.

Latest articles

Salle de presse Scientists at the CRCHUM find that a bacterium called...
Robin Monotti I think for three years there’s been a fight over...
William S. Bathgate Building Biology Environmental Consultant William S. Bathgate discusses the...
Lloyd Burrell Electricity was originally introduced to the mass population in the...
Mudan Cai and Eun Jin Yang Background: Amyotrophic lateral sclerosis (ALS) is a...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!